Want to see TSE:VXL full AI Analyst Report?
VXL Stock Chart & Stats
C$0.17
C$0.00(0.00%)
At close: 4:00 PM EDT
C$0.17
C$0.00(0.00%)
Day’s Range― - ―
52-Week RangeC$0.13 - C$0.29
Previous CloseN/A
Volume0.00
Average Volume (3M)1.45K
Market Cap
C$697.20K
Enterprise ValueC$0.07
Total Cash (Recent Filing)C$527.00K
Total Debt (Recent Filing)C$0.00
Price to Earnings (P/E)1.3
Beta-1.01
Next Earnings
Aug 31, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.13
Shares Outstanding3,984,021
10 Day Avg. Volume1,125
30 Day Avg. Volume1,453
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.30
Price to Sales (P/S)0.00
P/FCF Ratio-2.42
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetZero debt reduces solvency risk and interest burden, giving management flexibility to fund clinical programs and pursue R&D without immediate refinancing. For a clinical-stage biotech, a debt-free capital structure supports runway and strategic optionality over the next several months.
Immunotherapy Clinical FocusA focus on T‑cell immunotherapy in oncology and infectious disease targets durable, high-need markets with long-term demand. If clinical progress is achieved, the platform approach can create sustainable competitive advantages and significant commercial upside over a multi‑quarter horizon.
Improving Cash Burn TrendReduced cash burn versus prior years indicates improved cost control and extends operational runway, lowering immediate financing pressure. If this efficiency trend persists, it enhances the company's ability to fund clinical activities and execute strategy over the medium term.
Bears Say
No Revenue; Persistent Operating LossesThe absence of revenue and consistently negative EBIT mean the company has no operating cash inflows to self-fund development. This structural reliance on external capital increases dilution and constrains long-term scaling unless clinical programs produce clear, fundable milestones.
Negative Operating And Free Cash FlowPersistent negative operating and free cash flow (TTM ~‑267k) demonstrates ongoing cash burn; absent material revenue or partnership inflows the firm will require additional funding. Recurring financing needs can be dilutive and may slow program timelines or strategic initiatives.
Earnings Quality And VolatilityPositive net income driven while operating cash flow stays negative suggests earnings rely on non‑operating items or timing effects. This reduces confidence in the repeatability of profits, complicates forecasting and strategic planning for investors and management over coming quarters.
Vaxil Bio News
VXL FAQ
What was Vaxil Bio Ltd’s price range in the past 12 months?
Vaxil Bio Ltd lowest stock price was C$0.13 and its highest was C$0.29 in the past 12 months.
What is Vaxil Bio Ltd’s market cap?
Vaxil Bio Ltd’s market cap is C$697.20K.
When is Vaxil Bio Ltd’s upcoming earnings report date?
Vaxil Bio Ltd’s upcoming earnings report date is Aug 31, 2026 which is in 25 days.
How were Vaxil Bio Ltd’s earnings last quarter?
Currently, no data Available
Is Vaxil Bio Ltd overvalued?
According to Wall Street analysts Vaxil Bio Ltd’s price is currently Overvalued.
Does Vaxil Bio Ltd pay dividends?
Vaxil Bio Ltd does not currently pay dividends.
What is Vaxil Bio Ltd’s EPS estimate?
Vaxil Bio Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Vaxil Bio Ltd have?
Vaxil Bio Ltd has 3,984,021 shares outstanding.
What happened to Vaxil Bio Ltd’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Vaxil Bio Ltd?
Currently, no hedge funds are holding shares in TSE:VXL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Vaxil Bio Ltd
Vaxil Bio Ltd. is a biotechnology firm dedicated to discovering and developing innovative therapeutic agents. Its foundation lies in a unique signal peptide-based platform, which it leverages to address critical health challenges, specifically infectious diseases and various cancers. The company's primary therapeutic candidate, ImMucin, has successfully advanced through Phase I/II clinical trials as a potential treatment for multiple myeloma. Beyond ImMucin, Vaxil Bio is actively developing a vaccine/treatment for tuberculosis, as well as a vaccine targeting coronavirus (COVID-19). Strategic alliances bolster its research efforts; Vaxil Bio collaborates with The Tel Aviv Sourasky Medical Center on a research initiative to create a peptide-based COVID-19 vaccine. Furthermore, it holds a Cooperative Research and Development Agreement with the U.S. Army Medical Research Institute of Infectious Diseases to assess CorVax's efficacy in preventing COVID-19 in murine models. Established in 2006, the company's operations are based in Toronto, Canada.
Technical Analysis
―
Medicenna Therapeutics Corp
―
BriaCell Therapeutics
―
BioVaxys Technology
―
Defence Therapeutics
―